Tridegin
Factor XIIIa inhibitor — blocks fibrin cross-linking; novel mechanism distinct from hirudin.
Praeklinisch / mechanistischLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Factor XIIIa inhibitor — blocks fibrin cross-linking; novel mechanism distinct from hirudin.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Tridegin's in vitro inhibition of Factor XIIIa does not establish clinical efficacy. No FDA-approved Factor XIIIa inhibitor exists. Mechanism is preclinical/biochemical only.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 8,400 Da
- Source species
- Haementeria ghilianii
- Discovered
- 1997 · Finney S et al.
Biological Targets
- → Factor XIIIa (transglutaminase)
Key Citations
- Finney S et al. (1997), Biochem J · PMID 9210403
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.